Sansheng Guojian: Summary of 2025 Semi-annual Report
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2025 Semi-Annual Report Summary Company Code: 688336 Company Abbreviation: Sunshine Guojian
Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd.
2025 Interim Report Summary
Summary of 2025 Semi-Annual Report of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Section 1 Important Tips
1.1 The summary of this semi-annual report comes from the full text of the semi-annual report, in order to fully understand the company’s operating results, financial status and future development.
For planning, investors should go to the Shanghai Stock Exchange website (www.sse.com.cn) to carefully read the full text of the semi-annual report.
1.2 Major risk warning
The company has elaborated on the company's core competitiveness risks, operating risks, industry risks and other risk factors in this report. Please refer to the "Risk Factors" in Section 3 of this report, "Management Discussion and Analysis", and investors are reminded to pay special attention to the following risks:
- Innovative drug research and development faces uncertainty and the risk of greater market competition.
The research and development of innovative drugs has the characteristics of long research and development cycle, heavy investment, high risk and low success rate. From project establishment to new drug approval for marketing, it must go through many complex links such as preclinical research, clinical trials, new drug registration and marketing, and after-sales supervision. Each link may face the risk of failure. In addition, taking into account the risks of drug research and development and the uncertainty of market competition for future product launches, if the company cannot effectively utilize its R&D technology experience, large-scale production advantages or terminal sales coverage capabilities, it may result in products under development being unable to be approved for marketing first among products with the same target, and related products will face a more competitive market environment, which will have an adverse impact on the growth and sustainable profitability of the company's operating performance. In the future, the company needs to continue to conduct innovative drug research and development to ensure that the company continues to have new products for clinical practice and then on the market. However, the company cannot guarantee that it can continuously find indications with commercial value. The potential products screened by the company may not have the potential for further development due to insufficient effectiveness and other reasons. If the company is unable to continuously develop new products with commercial potential, it may have an adverse impact on the company's business.
- Risks of increased R&D investment and lower than expected sales growth of core products
In view of the continuous deepening of the company's R&D project process and the forward-looking layout of the future antibody drug R&D field, the initial investment in R&D projects has increased, and the R&D investment in ongoing projects has increased with the needs of their R&D stages. It is expected that the company will continue to incur a relatively large amount of R&D expenses in the future. If R&D expenses are greater than the profits generated from commercialized products, the company will suffer losses.
- Uncertainty risks in income growth caused by centralized procurement
From the perspective of medical insurance policies, the coverage of centralized drug purchasing will continue to expand, and the centralized purchasing of biosimilar drugs has also begun, which will bring uncertainty risks to the sales revenue growth of the company's main products.
1.3 The company’s board of directors, board of supervisors and directors, supervisors and senior managers guarantee the authenticity, accuracy and authenticity of the contents of the semi-annual report.
Completeness, no false records, misleading statements or major omissions, and bear individual and joint legal liability.
1.4 All directors of the company shall attend the board meeting.
1.5 This semi-annual report has not been audited.
1.6 The profit distribution plan for the reporting period or the plan for converting public reserve funds into share capital passed by the board of directors
The company plans to distribute a cash dividend of RMB 0.33 (tax included) to all shareholders for every 10 shares. As of June 30, 2025, the company's total share capital is 616,785,793 shares, and based on this calculation, the total cash dividend to be distributed is RMB 20,353,931.17 (tax included). The amount of this cash dividend accounts for 10.69% of the net profit attributable to ordinary shareholders of the listed company in the 2025 semi-annual consolidated statement.
1.7 Whether there are any important matters such as special arrangements for corporate governance
□Applicable √Not applicable
Summary of 2025 Semi-Annual Report of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Section 2 Basic Information of the Company
2.1 Company Profile
Company Stock Profile
Company Stock Profile
Stock type Stock listing exchange Stock abbreviation Stock code Stock abbreviation before change: RMB ordinary shares (A Shanghai Stock Exchange Section Sansheng Guojian 688336 Not applicable
shares) GEM
Company Depository Receipts Brief Introduction
□Applicable √Not applicable
Contact person and contact details
Contact and contact information Secretary of the Board of Directors (Domestic Information Disclosure Agent) Securities Affairs Representative
table)
Name Zhang Qi Zhang Fengzhan
Phone 021-80297676 021-80297676
Office address China (Shanghai) Pilot Free Trade Zone No. 399, Li Bing Road, China (Shanghai) Pilot Free Trade Zone No. 399, Li Bing Road
Email [email protected] [email protected]
2.2 Main financial data
Unit: 10,000 yuan Currency: RMB
The end of the reporting period is higher than the end of the previous year. The end of the reporting period is higher than the end of the previous year.
Increase or decrease(%)
Total assets 601,259.2 596,502.73 0.80 belongs to listed company shares
569,890.64 556,764.21 2.36 Dong’s net worth
This reporting period increased compared with the same period last year. The reporting period increased compared with the same period last year.
Less(%)
Operating income 64,201.34 59,661.97 7.61 Total profit 18,621.83 13,838.6 34.56 Attributable to shares of listed companies
19,032.24 12,951.05 46.96 Dong’s net profit
Attributable to listed company shares
Net profit after deducting non-recurring profits and losses 15,722.72 12,614.51 24.64
Cash generated from business activities
18,773.36 14,015.31 33.95 Net cash flow
weighted average net assets
3.38 2.62 Increased profit rate by 0.76 percentage points (%)
Basic earnings per share (yuan/
0.31 0.21 47.62 shares)
Diluted earnings per share (yuan / 0.31 0.21 47.62 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2025 Semi-annual Report Summary
shares)
R&D investment accounts for operating income
36.48 35.02 Proportion of income increasing by 1.46 percentage points (%)
2.3 List of shareholdings of the top 10 shareholders
Unit: Share Total number of shareholders as of the end of the reporting period (households) 12,842 Total number of preference shareholders with restored voting rights as of the end of the reporting period (households) 0 Total number of shareholders holding shares with special voting rights as of the end of the reporting period (households) 0 Shareholding status of the top 10 shareholders
Holdings include refinancing holdings
Shareholding Restriction clause Lending shares Pledge, mark or freeze shareholder name Nature of shareholder Ratio
Number of pieces of restricted shares Number of shares settled (%)
Number of shares Number of shares Fujian Pharmaceutical Co., Ltd. Overseas legal person 35.92 221,518,988 0 None Shanghai Xingsheng Pharmaceutical Co., Ltd. Domestic non-national
34.48 212,658,228 0 No legal person
Shenyang 3SBio Pharmaceutical Co., Ltd. Domestic non-national
6.42 39,614,607 0 No company with legal person
Dajia International (Hong Kong) has
Overseas legal person 4.08 25,160,657 0 Unlimited company
Shanghai Pudong Tianyu Investment Development
Others 1.78 10,965,428 0 No Exhibition Center (Limited Partnership)
Grand Path Holdings
Overseas legal person 1.69 10,408,922 0 None Limited
Shanghai Pudong Lingyu Investment Development
Others 0.71 4,375,655 0 No exhibition center (limited partnership)
Shanghai Xianyu Investment Consulting Co., Ltd. Domestic non-national
0.60 3,717,472 0 Unlimited company with legal person
China Construction Bank Co., Ltd.
Ltd.-In front of ICBC Credit Suisse
Others 0.52 3,199,043 0 Wujian Medical Equity Securities Investment
capital fund
Industrial and Commercial Bank of China Co., Ltd.
Co., Ltd. – Sino-Europe Medical Healthcare
Others 0.50 3,055,505 0 Wukang mixed securities investment fund
gold
The above-mentioned shareholders are related or acting in concert: 1. The seven shareholders of Fujian Pharmaceutical, Xingsheng Pharmaceutical, Shenyang Sansheng, Hong Kong Dajia, Pudong Tianxinyu, GrandPath, and Shanghai Hongen are all actually controlled by LOUJING;
- Shenyang Sansheng directly holds 100% of the equity of Shanghai Hongen Entropy; Shanghai Hongsheng directly holds 96.25% of the equity of Xingsheng Pharmaceutical; 3. Shenyang Sansheng directly holds 23.50% of the capital contribution share of Pudong Tianyu, and indirectly holds Pudong Tianyu through its wholly-owned subsidiary Liaoning Sansheng
76.50% of the investment share, total direct and indirect holdings of Pudong Tianyu’s 100% investment in Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2025 Semi-annual Report Summary
share. 4. The company does not know whether there is a related relationship among the above-mentioned other shareholders of unrestricted tradable shares or whether they are acting in concert as stipulated in the "Administrative Measures for Acquisitions of Listed Companies"
people.
Preference shareholders with restored voting rights and shareholdings
Not applicable
Description of quantity
2.4 Table of the top ten domestic depositary receipt holders
□Applicable √Not applicable
2.5 Table of top ten shareholders by number of voting rights as of the end of the reporting period
□Applicable √Not applicable
2.6 The total number of preference shareholders and the top 10 preference shareholders as of the end of the reporting period □ Applicable √ Not applicable
2.7 Changes in controlling shareholders or actual controllers
□Applicable √Not applicable
2.8 Status of bonds existing on the date of approval of the semi-annual report
□Applicable √Not applicable
Section 3 Important Matters
The company shall, in accordance with the principle of materiality, explain the major changes in the company's operating conditions during the reporting period, as well as the matters that occurred during the reporting period that have a significant impact on the company's operating conditions and are expected to have a significant impact in the future.
□Applicable √Not applicable